

Personal Information



Naiyarat Prasongsook

Address: Phramongkutklo Hospital

Country: Thailand

Curriculum Vitae

Education:

2000 M.D. Phramongkutklo College of medicine, Mahidol University, Bangkok, Thailand

Postdoctoral Training:

Internship and Residency:

- Internship in internal medicine, Kai Prajak Hospital, Udonthani, Thailand.
- 2002-05 Senior Resident in Medicine, Phramongkutklo, Bangkok, Thailand
- 2004-05 Chief Resident, Division of Internal Medicine, Phramongkutklo, Bangkok, Thailand

Fellowship:

- 2006-08 fellowship in Medical oncology, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
- 2012-14 Postdoctoral research fellow, Medical Oncology, Mayo Clinic, Rochester, MN
- 2012-14 Master degree in Bioscience and Clinical Translational Research Program, Mayo Graduate School, Rochester, MN

Licensure and Certification:

- Thai Physician Registration No.25954
- Diplomat, Thai Board of Internal Medicine
- Diplomat, Thai Board of Medical oncology
- Master degree in Bioscience and Clinical Translational Research
- Certification of Good Clinical Practice (GCP)
- Certification of the Ethical Oversight of Human Subjects Research, the Boston University School of Medicine

Current position

- 2008 – 2012, Instructor and co-investigator in Medical Oncology, Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Phramongkutklo Hospital.

- 2012-2014 Research fellow, Medical Oncology, Mayo Clinic, Rochester, MN
- June 2014- present Instructor and co-investigator in Medical Oncology, Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Phramongkutklao Hospital.
- October 2014 – present Stewardship, Thai Society Of Clinical Oncology (TSCO)
- May 2017-present Committee on biomedical research, Central Research Ethics Committee, Thailand.

Research:

1. Comparison of quality of life in end-stage kidney disease between twice and thrice weekly
2. Lung cancer in Ramathibodi Hospital; 2000-07
3. Treatment outcome of EGFR TKI in Thai patients who are diagnosed advanced NSCLC.
4. Efficacy of bevacizumab plus chemotherapy as the first-line treatment for patients with advanced non-small cell lung cancer: Thai Experience from Avastin Lung Cancer Programme for Thai Patients (ALPHA) project
5. Comparison of clinical benefits for each enrollment type treated with EGFR TKI for advanced non-small cell lung cancer (NSCLC) for the purpose of determining the selective suitability for use with unselected patients
6. Prevalence of HER2 positive gastric cancer in Phramongkutklao Hospital
7. Malignant spinal cord compression: a prospective of clinical practice
8. Clinical trials of pharmaceutical companies (Principle Investigator)
 - FASTACT II study in advanced NSCLC
 - CASA4042302 study in advanced NSCLC
 - SACTS study in locally advanced hepatocellular carcinoma
 - A6181122 study in unresectable/metastasis colorectal cancer
 - A Phase 3 randomized, double-blind study of PF-06439535 plus paclitaxel-carboplatin and bevacizumab plus paclitaxel-carboplatin for the first-line treatment of patients with advanced non-squamous non-small cell lung cancer
 - MK3475-042: A randomized, open-label, phase III study of overall survival comparing pembrolizumab (MK3475) versus platinum based chemotherapy in treatment naive subjects with PD-L1 positive advanced or metastatic non-small cell lung cancer (Keynote 042)
 - CLEE011A2404, An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormonal receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
 - A Global, randomized, Phase III, open-label study of REGN2810 (anti PD-1 antibody) versus platinum-based chemotherapy in first-line treatment of patients with advanced or metastatic PD-L1+ non-small cell cancer
9. Improving Overall Survival in Anaplastic Thyroid Carcinoma (ATC): the Mayo Clinic Experience
10. Translational Studies of Protandim[®] as a Candidate Nutraceutical Approach to Treating Ovarian Cancer

Awards and Honors:

1. 2003, Best-performance Internal Medicine Resident Award, Division of Internal Medicine, Phramongkutklao hospital, Bangkok, Thailand
2. 2004, Best-performance Internal Medicine Resident Award, Division of Internal Medicine, Phramongkutklao hospital, Bangkok, Thailand

3. 2005, Best-performance Internal Medicine Resident Award, Division of Internal Medicine, Phramongkutklo hospital, Bangkok, Thailand
4. 2006, Research representative in The Royal College of Physicians Of Thailand Conference
5. 2008, Best award for fellowship research in Thai Society of Medical Oncology
6. Oral presentation in survival and prognostic factors of non-small cell lung cancer patients in Ramathibodi hospital at 7th Roche Asia Oncology Forum (RAOF2008)
7. 2009, ASCO Cancer Foundation International Development and Education Award Recipients
8. 2009, Extended Tour Award as a guest of mentors Drs. Gary H Lyman in medical oncology unit at Duke University Cancer Center, Durham, North Carolina, USA.
9. 2010, Poster presentation in abstract title of comparison of clinical benefits for each enrollment type treated with EGFR TKI for advanced non-small cell lung cancer (NSCLC) for the purpose of determining the selective suitability for use with unselected patients at 12th Central-European Lung Cancer Conference (CELCC).
10. 2011, Poster presentation in abstract title of Cost-effectiveness analysis (CEA) between Erlotinib and Gefitinib for patients with advanced Non-Small Cell Lung Cancer (NSCLC) in Thailand at 14th World Conference on Lung Cancer.
11. 2014, Publication in abstract title of Impact of Aggressive Combined-Modality Primary Therapy in Anaplastic Thyroid Carcinoma (ATC): An Updated Single-Institution Experience at ASCO 50th Annual meeting science and society.
12. 2017, program committee of the International Association for the study of Lung Cancer (IASLC) 18th, World Conference in Lung Cancer (WCLC).

Memberships

- 2005-present, Royal College of Physicians of Thailand
- 2007-present, Membership of American Society of Clinical Oncology
- 2008-present, Membership of Thai Society of Clinical Oncology
- 2010-present, Membership of European Society for Medical Oncology
- 2011-present, Membership of International Association for the Study of Lung Cancer
- 2013, Membership of American Association for Cancer Research

Area of interest

1. Biology and update management of endocrine malignancy, lung cancer, breast cancer and hepatobiliary cancer
2. Biochemical pharmacology of anti-neoplastic agents and molecular agent
3. Clinical research in oncology
4. Palliative care

Selected Peer-reviewed Publications

Abstracts:

1. Prasongsook, N., Maoleekul, S., Sirisingha, T. 2010. Comparison of clinical benefits for each enrollment type treated with EGFR TKI for advanced non-small cell lung cancer (NSCLC) for the purpose of determining the selective suitability for use with unselected patients. Abstract for presentation, American Society of Clinical Oncology (ASCO) annual meeting, Chicago, IL
2. Prasongsook, N., Maoleekul, S., Jaruhathai, S. 2011. Cost-effectiveness analysis (CEA) between Erlotinib and Gefitinib for patients with advanced Non-Small Cell Lung Cancer (NSCLC) in Thailand. Abstract for presentation, 14th World Conference on Lung Cancer, Amsterdam, Netherland.

3. Srimuninnimit, V., Sriuranpong, P., Pornprasertsuk, P., Thongprasert, S., Sookprasert, A., Sunpaweravong, P., Suwanpratheep, P., Sirachainan, A., Sorraritchingchai, S., Laohavinij, S., Chewaskulyong, B., Prasongsook, N. 2012. Final results and efficacy of Bevacizumab combined with Paclitaxel/Carboplatin in the First-line treatment of advanced Non-Small Cell Lung Cancer: Thai experience from Avastin Lung Cancer Program for Thai Patients (ALPHA) project. Abstract for presentation, Round Asia Oncology Forum (RAOF), Taipei, Taiwan.
4. Chakrabandhu S., Chitapanarux, I., Jiratrachu, R., Pruegsanusak, K., Pinitpatcharalerd, A., Sukhaboon, J., Tovanabutra, C., Srisuthep, A., Prasongsook, N., Lorvidhaya, V. 2012. The randomized study comparing the efficacy and safety of radiochemotherapy plus adjuvant chemotherapy (CCRT) versus neoadjuvant chemotherapy plus radiochemotherapy (NAC-RT) for locally advanced nasopharyngeal cancer. Abstract for presentation, European Society for Medical Oncology (ESMO), Vienna, Austria.

Publications

1. Prasongsook, N., Peethambarum, Prema P., Shridhar, Vijayalakshmi., Suman Vera J., Bible, Keith C. Translational Studies of Protandim (RTM) as a Candidate Nutraceutical Approach to Treating Ovarian Cancer. MAI 52/06(E), Dec 2014, Ann Arbor, United States, ISBN 9781303883163.
2. Prasongsook N, Foote RL, Molina JR, Kasperbauer JC, Garces YI, Ma D, Rubin J, Richardson RL, Hay ID, Fatourechi V, McIver B, Morris JC, Thompson GB, Grant CS, Richards ML, Suman VJ, Bible KC. Impact of aggressive combined-modality primary therapy in anaplastic thyroid carcinoma (ATC): An updated single-institute experience. J Clin Oncol 2014; 32: suppl; abstr e 17042.
3. Rittiluechai K, Prasongsuk N, Vinh-Hung V, Verschraegen C. Ovarian Cancer-Angiogenesis and Targeted Therapy. Current Angiogenesis 2014; 3: 215 – 230.
4. Chaisakul J, Hodgson WC, Kuruppu S, Prasongsook N. Effects of Animal Venoms and Toxins on Hallmarks of Cancer. J Cancer 2016; 7(11): 1571-1578.
5. Prasongsook N. Explanation model using pathological data for treatment outcome of patients with early-stage breast cancer with hormonal receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative. J Clin Oncol 2017; 35: 15_suppl.e12006.
6. ไนยรัฐ ประสงค์สุข. Tumor Markers in Clinical Practice. In: จันทราภา ศรีสวัสดิ์, ประเจษฎ์ เรืองกาญจนเศรษฐ์, ธาระพันธ์ พิบูลย์บรรณกิจ, วิชัย ประยูรวิวัฒน์, eds. การดูแลผู้ป่วยนอกทางอายุรศาสตร์. กรุงเทพฯ: นำอักษรการพิมพ์; 2552: 496-511.
7. ไนยรัฐ ประสงค์สุข. Palliative and End-of-Life Care. In: จันทราภา ศรีสวัสดิ์, ประเจษฎ์ เรืองกาญจนเศรษฐ์, วิชัย ประยูรวิวัฒน์, eds. Common Problems in Internal Medicine. กรุงเทพฯ: นำอักษรการพิมพ์; 2553: 451-464.
8. ไนยรัฐ ประสงค์สุข. Breast Mass. In: บัญชา สติระพจน์, อุปลักษณ์ ศุกสินธุ์, จันทราภา ศรีสวัสดิ์, วิชัย ประยูรวิวัฒน์, eds. อากาโรอายุรศาสตร์. กรุงเทพฯ: นำอักษรการพิมพ์; 2554: 101-106.
9. ไนยรัฐ ประสงค์สุข. Breast Cancer. In: อำนวย ชัยประเสริฐ, ประเจษฎ์ เรืองกาญจนเศรษฐ์, จันทราภา ศรีสวัสดิ์, วิชัย ประยูรวิวัฒน์, eds. Practical Points in Internal Medicine. กรุงเทพฯ: นำอักษรการพิมพ์; 2554: 61-70.
10. ไนยรัฐ ประสงค์สุข. การแข็งขาารร้าย. In: ชำรงค์รัตน์ แก้วกาญจน์, สุจินต์ อุบลวัตร, วิชัย ประยูรวิวัฒน์, eds. เวชจริยธรรม. กรุงเทพฯ: นำอักษรการพิมพ์; 2554: 159-161.
11. ไนยรัฐ ประสงค์สุข. Common Solid Tumors. In: บัญชา สติระพจน์, เนาวนิตย์ นาทา, สิริกานต์ เตชะวณิช, อภิชัย ลีละศิริ, วิชัย ประยูรวิวัฒน์, eds. Clinical Approach in Medicine. กรุงเทพฯ: นำอักษรการพิมพ์; 2557: 173-180.
12. ไนยรัฐ ประสงค์สุข. Superior Vena Cava Syndrome. In: อุปลักษณ์ ศุกสินธุ์, ศศิโสภิน เกียรติบูรณกุล, ยิ่งยง ชินธรรมมิตร, สมิง เก่าเจริญ, eds. คู่มือการดูแลผู้ป่วยทางอายุรศาสตร์. กรุงเทพฯ: เนติกุลการพิมพ์; 2557: 413-421.

13. ไนยรัฐ ประสงค์สุข. Basic Medical Oncology. In: เนาวนิตย์ นาทา, กานดิษฐ์ ประยงค์รัตน์, จันทราภา ศรีสวัสดิ์, วิชัย ประยูรวิวัฒน์, eds. Introduction to Clinical Medicine. กรุงเทพฯ: นำอักษรการพิมพ์; 2558: 161-163.
14. ไนยรัฐ ประสงค์สุข. Cancer Pain Management. In: อานาจ ชัยประเสริฐ, ตันตณัย นำเบญจพล, สิริกานต์ เตชะวณิช, จันทราภา ศรีสวัสดิ์, วิชัย ประยูรวิวัฒน์, eds. Emergency Medicine. กรุงเทพฯ: นำอักษรการพิมพ์; 2558: 157-164.
15. ไนยรัฐ ประสงค์สุข. Modern Modalities in Cancer Treatment (การรักษามะเร็งแนวใหม่). In: กวีศักดิ์ จิตตวัฒน์รัตน์, ปณต ยิ้มเจริญ, ปวัน จันทน์แสนโรจน์, วิฑูร ชินสว่างวัฒน์กุล, สุขไชย สาทถาวร, สุรศักดิ์ สังขทัต ณ อยุรยา, eds. Fundamental Surgical Science. กรุงเทพฯ: สำนักพิมพ์กรุงเทพเวชสาร; 2558: 406-423.